Merit Medical Systems (NASDAQ:MMSI – Get Rating) had its price objective hoisted by equities research analysts at Needham & Company LLC  from $78.00 to $84.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Needham & Company LLC’s target price indicates a potential upside of 10.44% from the stock’s current price.

MMSI has been the subject of a number of other research reports. Barrington Research  reaffirmed an “outperform” rating and issued a $78.00 price objective on shares of Merit Medical Systems in a research note on Wednesday, April 12th. Raymond James increased their price objective on shares of Merit Medical Systems from $80.00 to $86.00 and gave the company an “outperform” rating in a research note on Monday. Canaccord Genuity Group lowered Merit Medical Systems from a “buy” rating to a “hold” rating and decreased their price objective for the company from $73.00 to $72.00 in a research report on Tuesday, December 20th. StockNews.com raised shares of Merit Medical Systems from a “buy” rating to a “strong-buy” rating in a report on Friday, April 14th. Finally, Piper Sandler raised their target price on shares of Merit Medical Systems from $73.00 to $77.00 and gave the stock an “overweight” rating in a report on Thursday, February 23rd. One equities research analyst  has rated the stock with a hold rating, five have given a buy rating and one  has given a strong buy rating to the company’s stock. According to MarketBeat, Merit Medical Systems presently has a consensus rating of “Buy” and a consensus price target of $78.33.

MMSI opened at $76.06 on Wednesday. The company’s 50 day simple moving average is $71.39 and its 200 day simple moving average is $69.13. Merit Medical Systems has a 1 year low of $50.46 and a 1 year high of $77.70. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.19 and a current ratio of 2.40. The stock has a market capitalization of $4.37 billion, a PE ratio of 58.51, a P/E/G ratio of 2.47 and a beta of 0.99.

Merit Medical Systems (NASDAQ:MMSI – Get Rating) last announced its quarterly earnings data on Wednesday, February 22nd. The medical instruments supplier reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.12. The firm had revenue of $293.40 million for the quarter, compared to analysts’ expectations of $290.14 million. Merit Medical Systems had a return on equity of 14.28% and a net margin of 6.47%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the business posted $0.71 earnings per share.  As a group, sell-side analysts expect that  Merit Medical Systems will post 2.85 EPS for the current year.

In other news, CFO Raul Jr. Parra sold 1,023 shares of the company’s stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $70.00, for a total transaction of $71,610.00. Following the transaction, the chief financial officer now owns 6,688 shares in the company, valued at $468,160. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Merit Medical Systems news, CFO Raul Jr. Parra sold 1,023 shares of the business’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $70.00, for a total transaction of $71,610.00. Following the completion of the sale, the chief financial officer now directly owns 6,688 shares of the company’s stock, valued at approximately $468,160. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Fred P. Lampropoulos sold 1,483 shares of the stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $70.17, for a total value of $104,062.11. Following the completion of the sale, the chief executive officer now directly owns 1,012,069 shares of the company’s stock, valued at $71,016,881.73. The disclosure for this sale can be found here. Insiders have sold a total of 64,068 shares of company stock valued at $4,341,157 over the last 90 days. 3.80% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its position in shares of  Merit Medical Systems by 26.1% during the first quarter. JPMorgan Chase & Co. now owns 136,214 shares of the medical instruments supplier’s stock worth $9,061,000 after acquiring an additional 28,233 shares in the last quarter.  American Century Companies Inc. increased its position in shares of  Merit Medical Systems by 17.9% during the 1st quarter. American Century Companies Inc. now owns 9,016 shares of the medical instruments supplier’s stock valued at $600,000 after purchasing an additional 1,369 shares during the last quarter.  Citigroup Inc. raised its stake in shares of  Merit Medical Systems by 8.1% during the first quarter. Citigroup Inc. now owns 49,073 shares of the medical instruments supplier’s stock worth $3,265,000 after acquiring an additional 3,685 shares in the last quarter.  MetLife Investment Management LLC raised its position in  Merit Medical Systems by 55.0% in the 1st quarter. MetLife Investment Management LLC now owns 28,593 shares of the medical instruments supplier’s stock worth $1,902,000 after purchasing an additional 10,143 shares during the period.  Finally, Rhumbline Advisers lifted its stake in shares of  Merit Medical Systems by 4.3% in the 1st quarter. Rhumbline Advisers now owns 132,266 shares of the medical instruments supplier’s stock valued at $8,798,000 after acquiring an additional 5,501 shares during the last quarter. Institutional investors own  95.38% of the company’s stock.

Merit Medical Systems, Inc engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups.

Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.